Please use this identifier to cite or link to this item:
10.1016/j.ijid.2019.03.036
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | The members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring | - |
dc.contributor.author | Kuksa, Liga | - |
dc.contributor.author | Šmite, Agnese | - |
dc.date.accessioned | 2021-06-12T13:55:01Z | - |
dc.date.available | 2021-06-12T13:55:01Z | - |
dc.date.issued | 2019-06 | - |
dc.identifier.citation | The members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring , Kuksa , L & Šmite , A 2019 , ' Surveillance of adverse events in the treatment of drug-resistant tuberculosis : A global feasibility study ' , International Journal of Infectious Diseases , vol. 83 , pp. 72-76 . https://doi.org/10.1016/j.ijid.2019.03.036 | - |
dc.identifier.issn | 1201-9712 | - |
dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/4933 | - |
dc.description | Publisher Copyright: © 2019 | - |
dc.description.abstract | The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries. The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs. Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile. A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019. | en |
dc.format.extent | 5 | - |
dc.format.extent | 794730 | - |
dc.language.iso | eng | - |
dc.relation.ispartof | International Journal of Infectious Diseases | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.subject | Adverse events | - |
dc.subject | Bedaquiline | - |
dc.subject | Delamanid | - |
dc.subject | MDR-TB | - |
dc.subject | Monitoring | - |
dc.subject | Tuberculosis | - |
dc.subject | 3.2 Clinical medicine | - |
dc.subject | 1.1. Scientific article indexed in Web of Science and/or Scopus database | - |
dc.subject | Microbiology (medical) | - |
dc.subject | Infectious Diseases | - |
dc.subject | SDG 3 - Good Health and Well-being | - |
dc.title | Surveillance of adverse events in the treatment of drug-resistant tuberculosis : A global feasibility study | en |
dc.type | /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article | - |
dc.identifier.doi | 10.1016/j.ijid.2019.03.036 | - |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85065097630&partnerID=8YFLogxK | - |
dc.description.status | Peer reviewed | - |
Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Surveillance_of_adverse_events.pdf | 776.1 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.